Top

Published in:

Open Access 01-12-2024 | Metastasis | Research

Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China

Authors: Zhongshi Xie, Qichen Chen, Bo Feng, Yujuan Jiang, Xin Wang, Wei Xing, Qian Liu, on behalf of the Chinese Lateral Node Collaborative Group

Published in: BMC Cancer | Issue 1/2024

Abstract

Aims

Selective lateral pelvic lymph node (LPN) dissection (LPND) following neoadjuvant chemoradiotherapy (nCRT) for rectal cancer is widely recognized. This study aimed to determine the effects of nCRT before LPND on local control and prognosis of rectal cancer patients.

Materials and methods

Data were retrieved from a prospective database for rectal cancer patients with clinical LPN metastasis receiving total mesorectal excision and LPND at three institutions between January 2012 and December 2019. Selection bias was minimized using propensity score matching (PSM) and short-term and clinical outcomes were compared.

Results

Patients (n = 213) were enrolled and grouped as either nCRT (n = 97) or non-nCRT (n = 116). PSM was used to identify 83 matched pairs. In the matched cohort, nCRT patients had a longer operation duration (310.6 vs. 265.0 min, P = 0.001), lower pathological LPN metastasis rate (32.5% vs. 48.2%, P = 0.040), and fewer harvested lymph nodes (22 vs. 25, P = 0.018) compared to the non-nCRT group. However, after PSM, the two groups had similar estimated overall 3-year survival (79.5% vs. 80.7%, P = 0.922), 3-year disease-free survival (66.1% vs. 65.5, P = 0.820), and 3-year local recurrence-free survival (88.6% vs. 89.7%, P = 0.927). Distant metastasis was the predominant recurrence pattern in the overall (45/58, 77.6%) and matched (33/44, 75.0%) cohorts.

Conclusions

LPND without nCRT is effective and sufficient in preventing local recurrence in patients with LPN metastases. Future prospective randomized controlled studies are warranted to confirm these findings. Since systemic metastasis is the predominant recurrence pattern in patients with LPN metastasis post-LPND, improved perioperative systemic chemotherapy is needed to prevent micrometastasis.

Huang X, Xiang JB. Progress in the surgical treatment of locally recurrent rectal cancer. Chin J Colorec Dis (Electronic Edition). 2021;10:643–7. https://doi.org/10.3877/cma.j.issn.2095-3224.2021.06.012CrossRef

Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K, et al. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255:1129–34. https://doi.org/10.1097/SLA.0b013e3182565d9dCrossRefPubMed

Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42. https://doi.org/10.1007/s10147-019-01485-zCrossRefPubMed

Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, et al. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017;266:201–7. https://doi.org/10.1097/SLA.0000000000002212CrossRefPubMed

Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184–90. https://doi.org/10.1016/S1470-2045(13)70599-0CrossRefPubMed

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23. https://doi.org/10.1056/NEJMoa060829CrossRefPubMed

Yang X, Gu C, Hu T, Wei M, Meng W, Wang Z, et al. Indications and oncological outcomes of selective dissection for clinically suspected lateral lymph node metastasis in patients with rectal cancer based on pretreatment imaging. Tech Coloproctol. 2021;25:425–37. https://doi.org/10.1007/s10151-020-02386-4CrossRefPubMed

Kawai K, Shiratori H, Hata K, Nozawa H, Tanaka T, Nishikawa T, et al. Optimal size criteria for lateral lymph node dissection after neoadjuvant chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2021;64:274–83. https://doi.org/10.1097/DCR.0000000000001866CrossRefPubMed

Zhou S, Jiang Y, Pei W, Zhou H, Liang J, Zhou Z. Neoadjuvant chemoradiotherapy followed by lateral pelvic lymph node dissection for rectal cancer patients: a retrospective study of its safety and indications. J Surg Oncol. 2021;124:354–60. https://doi.org/10.1002/jso.26509CrossRefPubMed

10.

Nicholls RJ, Zinicola R, Haboubi N. Extramural spread of rectal cancer and the AJCC Cancer Staging Manual;30. 8th ed. Ann Oncol 2019; 2017, p. 1394–5.

11.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96. https://doi.org/10.1097/SLA.0b013e3181b13ca2CrossRefPubMed

12.

Wang P, Zhou S, Zhou H, Liang J, Zhou Z. Evaluating predictive factors for determining the presence of lateral pelvic node metastasis in rectal cancer patients following neoadjuvant chemoradiotherapy. Colorectal Dis. 2019;21:791–6. https://doi.org/10.1111/codi.14595CrossRefPubMed

13.

Ogura A, Konishi T, Cunningham C, Garcia-Aguilar J, Iversen H, Toda S, et al. Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3/4 rectal cancer. J Clin Oncol. 2019;37:33–43. https://doi.org/10.1200/JCO.18.00032CrossRefPubMed

14.

Lirici MM, Hüscher CG. Techniques and technology evolution of rectal cancer surgery: a history of more than a hundred years. Minim Invasive Ther Allied Technol. 2016;25:226–33. https://doi.org/10.1080/13645706.2016.1198381CrossRefPubMed

15.

Ogura A, Akiyoshi T, Nagasaki T, Konishi T, Fujimoto Y, Nagayama S, et al. Feasibility of laparoscopic total mesorectal excision with extended lateral pelvic lymph node dissection for advanced lower rectal cancer after preoperative chemoradiotherapy. World J Surg. 2017;41:868–75. https://doi.org/10.1007/s00268-016-3762-0CrossRefPubMed

16.

Mori S, Baba K, Yanagi M, Kita Y, Yanagita S, Uchikado Y, et al. Laparoscopic complete mesocolic excision with radical lymph node dissection along the surgical trunk for right colon cancer. Surg Endosc. 2015;29:34–40. https://doi.org/10.1007/s00464-014-3650-3CrossRefPubMed

17.

Gurawalia J, Dev K, Nayak SP, Kurpad V, Pandey A. Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer? J Gastrointest Oncol. 2016;7:946–57. https://doi.org/10.21037/jgo.2016.09.03CrossRefPubMedPubMedCentral

18.

Zhu J, Liu A, Sun X, Liu L, Zhu Y, Zhang T, et al. Multicenter, randomized, Phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer. J Clin Oncol. 2020;38:4231–9. https://doi.org/10.1200/JCO.20.01932CrossRefPubMedPubMedCentral

19.

Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835–44. https://doi.org/10.1016/S1470-2045(10)70172-8CrossRefPubMed

20.

Yu L, Xu TL, Zhang L, Shen SH, Zhu YL, Fang H, et al. Impact of neoadjuvant chemoradiotherapy on the local recurrence and distant metastasis pattern of locally advanced rectal cancer: a propensity score-matched analysis. Chin Med J (Engl). 2021;134:2196–204. https://doi.org/10.1097/CM9.0000000000001641CrossRefPubMed

21.

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, et al. Randomized Phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019;37:3212–22. https://doi.org/10.1200/JCO.19.00308CrossRefPubMed

22.

Fernández-Martos C, Pericay C, Losa F, García-Carbonero R, Layos L, Rodríguez-Salas N, et al. Effect of aflibercept plus modified FOLFOX6 induction chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma: the GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019;5:1566–73. https://doi.org/10.1001/jamaoncol.2019.2294CrossRefPubMedPubMedCentral

Title: Can neoadjuvant chemoradiotherapy before lateral pelvic lymph node dissection improve local control and prognosis in rectal cancer patients with clinically suspected lateral lymph node metastasis? A multicenter lateral node study in China
Authors: Zhongshi Xie
Qichen Chen
Bo Feng
Yujuan Jiang
Xin Wang
Wei Xing
Qian Liu
on behalf of the Chinese Lateral Node Collaborative Group
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Metastasis
Rectal Cancer
Rectal Cancer
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-024-11867-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells

Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study

Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer

Retrospective validation study of an artificial neural network-based preoperative decision-support tool for noninvasive lymph node staging (NILS) in women with primary breast cancer (ISRCTN14341750)

Development and validation of a novel preoperative clinical model for predicting lymph node metastasis in perihilar cholangiocarcinoma

Proficiency testing of diagnosis in histopathology and immunohistochemistry of breast pathology in China: results from a pilot work of National Single Disease Quality Control Program for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer